• Skip to main content
  • Skip to footer

Akari Therapeutics

A Revolution in Treating Autoinflammatory & Orphan Diseases

Menu
  • HOME
  • ABOUT
    • Close
    • COMPANY OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
  • AREAS OF FOCUS
    • Close
    • PIPELINE
    • POSTERS & PUBLICATIONS
    • LEGACY PIPELINE ASSETS
  • INVESTOR RELATIONS
    • Close
    • OVERVIEW
    • GENERAL MEETING OF SHAREHOLDERS
      • Close
      • GENERAL MEETING
      • ANNUAL GENERAL MEETING
    • CORPORATE GOVERNANCE
      • Close
      • GOVERNANCE OVERVIEW
      • BOARD OF DIRECTORS
      • MANAGEMENT
      • COMMITTEE COMPOSITION
    • FINANCIAL INFORMATION
      • Close
      • SEC FILINGS
      • ANNUAL REPORTS
    • NEWS & PRESENTATIONS
      • Close
      • PRESS RELEASES
      • PRESENTATIONS
    • STOCK INFORMATION
      • Close
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
    • EMAIL ALERTS
  • PRESS
    • Close
    • PRESS RELEASES
    • STORIES
  • CONTACT US

Akari TX

Akari TX / December 18, 2024

Akari Therapeutics Announces Key Leadership Appointments

Samir R. Patel, M.D., appointed as Chief Executive Officer Abizer Gaslightwala appointed to Board of Directors BOSTON and LONDON, Dec. 18, 2024 (GLOBE …

[Read more...] about Akari Therapeutics Announces Key Leadership Appointments

Akari TX / December 16, 2024

Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

BOSTON and LONDON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) today announced the appointment of Torsten Hombeck, Ph.D. as Chief …

[Read more...] about Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

Akari TX / November 19, 2024

Akari Therapeutics Regains Full Nasdaq Compliance

-Shareholders Equity Deficiency has been Cured - Akari will Continue to be Listed and Traded on The Nasdaq Stock Market BOSTON and LONDON, November 19, 2024 …

[Read more...] about Akari Therapeutics Regains Full Nasdaq Compliance

Akari TX / November 14, 2024

Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

- Secures $3.2m in PIPE Financing - $50m Term Sheet Obtained for Available Financing under Equity Line of Credit BOSTON and LONDON, November 14, 2024 (GLOBE …

[Read more...] about Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

Akari TX / November 8, 2024

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio Inc. Merger

BOSTON and LONDON, November 8, 2024 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies …

[Read more...] about Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio Inc. Merger

« Previous Page
Next Page »

Footer

Follow Us

Terms of Use
Privacy Statement
Contact Us

Akari TX

Copyright © 2025 · Akari Therapeutics · Site Designed by Polus Digital, Inc.